These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. Refractory anemia and the myelodysplastic syndromes. Lawrence LW Clin Lab Sci; 2004; 17(3):178-86. PubMed ID: 15314893 [TBL] [Abstract][Full Text] [Related]
31. T-cell large granular lymphocyte proliferation in myelodysplastic syndromes: Clinicopathological features and prognostic significance. Zhang X; Sokol L; Bennett JM; Moscinski LC; List A; Zhang L Leuk Res; 2016 Apr; 43():18-23. PubMed ID: 26927701 [TBL] [Abstract][Full Text] [Related]
32. Paroxysmal nocturnal hemoglobinuria associated with in vitro inhibition of erythropoiesis by bone marrow T lymphocytes. Merchav S; Tatarsky I; Chezar J; Sharon R; Rosenbaum H; Schechter Y Isr Med Assoc J; 2000 Jan; 2(1):22-4. PubMed ID: 10892366 [TBL] [Abstract][Full Text] [Related]
33. [Proliferation of bone marrow hematopoietic stem cells and function of T helper lymphocytes of patients with immuno-related pancytopenia]. Fu R; Shao ZH; Liu H; He H; Sun J; Zhao MF; He GS; Shi J; Bai J; Yang TY; Yang CL Zhonghua Xue Ye Xue Za Zhi; 2004 Apr; 25(4):213-6. PubMed ID: 15182558 [TBL] [Abstract][Full Text] [Related]
34. [The content of lymphopoietic differentiation antigens on the membrane of blood lymphoid cells in patients with bone marrow hypoplasia studied using monoclonal antibodies]. Miterev GIu; Novikova MS; Bulycheva TI; Turbina NS; Mikhaĭlova EA Gematol Transfuziol; 1988 Oct; 33(10):10-5. PubMed ID: 3265120 [No Abstract] [Full Text] [Related]
35. Treating myelodysplastic syndromes. Ryan C; McCann S IDrugs; 2005 Apr; 8(4):320-6. PubMed ID: 15800807 [TBL] [Abstract][Full Text] [Related]
36. Deviation of type I and type II T cells and its negative effect on hematopoiesis in myelodysplastic syndrome. Wu L; Li X; Chang C; Ying S; He Q; Pu Q Int J Lab Hematol; 2008 Oct; 30(5):390-9. PubMed ID: 19046314 [TBL] [Abstract][Full Text] [Related]
37. Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression. Kochenderfer JN; Kobayashi S; Wieder ED; Su C; Molldrem JJ Blood; 2002 Nov; 100(10):3639-45. PubMed ID: 12393644 [TBL] [Abstract][Full Text] [Related]
38. Novel immunosuppressive strategies for bone marrow failure syndromes: a focus on alemtuzumab. Selleri C; Serio B; Risitano AM Mini Rev Med Chem; 2011 Jun; 11(6):536-43. PubMed ID: 21561402 [TBL] [Abstract][Full Text] [Related]
39. Antigen-recognition sites of micromanipulated T cells in patients with acquired aplastic anemia. Piao W; Grosse J; Czwalinna A; Ivanyi P; Ganser A; Franzke A Exp Hematol; 2005 Jul; 33(7):804-10. PubMed ID: 15963856 [TBL] [Abstract][Full Text] [Related]
40. Determining which patients with myelodysplastic syndrome will respond to immunosuppressive treatment. Barrett J; Sloand E; Young N Haematologica; 2006 May; 91(5):583-4. PubMed ID: 16670061 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]